Loading asset research
Silence Therapeutics Plc American Depository Share
SLNNasdaq · USD · StocksQuote as of · Exchange session not verified$13.04
-2.03%
Today
SLN
Loading 1D prices…
Market cap
$809.2M
Volume
685.9K
52w high
$17.5852w low
$4.19Company profile
Silence Therapeutics Plc American Depository Share
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
London, United States
Employees
88
CIK
1479615
Session & valuation
Open$13.32
Previous close$13.31
Day high$13.42
Day low$12.88
30-day avg. volume1.5M
Outstanding shares141.7M
Diluted EPS-$0.63
Latest annual period
P/E (trailing)-20.70
P/E (forward)-34.26
Price / book16.00
Beta1.44
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| CLYMClimb Bio Inc. Common Stock | $818.5M | $0.00 | — | -$0.88 | -4.85% | Buy |
| PHARPharming Group N.V. ADS each representing 10 ordinary shares | $793.4M | $376.1M | +0.76% | $0.04 | +3.75% | Buy |
| CYRXCryoPort Inc. Common Stock | $787.6M | $176.2M | +44.44% | $1.40 | +1.83% | Buy |
| NVCTNuvectis Pharma Inc. Common Stock | $783.1M | $0.00 | — | -$1.32 | +6.89% | Buy |
| ACRSAclaris Therapeutics Inc. Common Stock | $783.1M | $7.8M | -829.58% | -$0.53 | -3.45% | Buy |